Classification of evidence
PD
The primary research question was to examine the safety and tolerability and PD effects of batoclimab in patients with generalized MG. This study provides Class I evidence that, for patients with generalized MG, SC batoclimab injections are well tolerated, and that IgG and anti‐AChR antibody levels were significantly reduced at 6 weeks post‐baseline.